Echo Therapeutics, Inc. engages in the development of transdermal skin permeation
and diagnostic medical devices for wearable-health consumer and diabetes outpatient
markets. It is developing continuous glucose monitoring (CGM) system, a needle-free
wireless continuous glucose monitoring system in a hospital setting in the European
Union. The company has a licensing agreement with Ferndale Pharma Group, Inc. to
develop, manufacture, distribute, and market devices for skin preparation prior to the
application of topical anesthetics or analgesics prior to a range of needle-based medical
procedures in North America, the United Kingdom, South America, Australia, New
Zealand, Switzerland, and other portions of the European Community. In addition, it has
a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market,
import, and sell CGM to medical facilities and individual consumers in South Korea; and
a license, development, and commercialization agreement with Medical Technologies
Innovation Asia, Ltd to research, develop, manufacture, and use CGM in the People's
Republic of China, Hong Kong, Macau, and Taiwan. The company was founded in 1989
and is headquartered in Iselin, New Jersey.
As of June 1 2016, ECTE looks to be bullish, for a 2 to 3 week hold. A purchase at a
price between $1.60 and $1.80 is safe and could bring you returns between 10% and
15% in the next 30 days. Be sure you place a stop loss at 5% below you buy price, and
don’t be greedy, a consistent 10% to 15% per month can help dealing with losses and
sometimes help bring in more profits.
Also please keep in mind we are not offer trading advice, we are just sharing an idea.
For real stock trading advice you should contact a professional financial advisor.